Andrew Hirsch (@dochirsch) 's Twitter Profile
Andrew Hirsch

@dochirsch

Pulmonologist, thrombosis doc, interests in all aspects of pulmonary vascular disease, acute and chronic PE and PH.

ID: 2213375362

calendar_today08-12-2013 05:07:01

295 Tweet

292 Followers

842 Following

Manual Of Medicine (@manualomedicine) 's Twitter Profile Photo

Summary of Agents That Modify Blood Coagulation (Anticoagulant, Antiplatelet and Fibrinolytics) - Read More about Anticoagulants and Fibrinolytics: manualofmedicine.com/topics/hematol… #meded #foamed #medtwitter #pharmacology

Summary of Agents That Modify Blood Coagulation (Anticoagulant, Antiplatelet and Fibrinolytics)

- Read More about Anticoagulants and Fibrinolytics: manualofmedicine.com/topics/hematol…

#meded #foamed #medtwitter #pharmacology
Andrew Hirsch (@dochirsch) 's Twitter Profile Photo

Just donated to #SunYouth Montreal for #PeepsAgainstHunger in the #HCWvsHunger competition. Come on #CanadianHCW join the cause and feel good.

The Lancet Haematology (@thelancethaem) 's Twitter Profile Photo

NEW: Our Profile on Professor Susan R Kahn, Director of the Centre of Excellence in Thrombosis and Anticoagulation Care (Montreal, Canada), describes her career dedicated to helping people with #thrombosis. thelancet.com/journals/lanha…

Jason Weatherald MD (@albertaphdoc) 's Twitter Profile Photo

Important to have more data on the safety of #DOACs in #CTEPH N=205 VTE rate 1.10 %/person-year on VKA and 0.32 %/person-year ON DOAC (P = 0.21). Total bleeding on VKA (2.52 %/person-year) and DOAC (2.52 %/person-year). sciencedirect.com/science/articl… Andrew Hirsch

Benzidia Ilham (@benzidiai) 's Twitter Profile Photo

🆕Happy to share our new article on safety and efficacy of DOAC vs VKA 💊 in CTEPH patient 🫁 : lnkd.in/e2ZEEXz6 A special thank you to Andrew Hirsch Professor Susan R Kahn and Chantal Robitaille #CTEPH #Anticoagulation #DOAC #VKA #PE #McGill #CETAC

Andrew Hirsch (@dochirsch) 's Twitter Profile Photo

Glad to share link to our study showing #DOAC was as safe and effective as #VKA in our patient population with #CTEPH, authors.elsevier.com/a/1hPsvBEfCrHGT Thanks to authors Professor Susan R Kahn Benzidia Ilham , Dr. D. Langleben, Dr JF Morin, Dr. A Abualsaud, Dr. C Robitaille, L. Lesenko and L. MacDonald

CNN (@cnn) 's Twitter Profile Photo

Donald Trump faced blowback this week from his GOP presidential rivals over his recent comments on abortion, in which he called Florida’s six-week abortion ban a “terrible mistake” and said that he’d be willing to work with both parties on the issue cnn.it/3RqsXXj

PERT Consortium (@pertconsortium) 's Twitter Profile Photo

March marks #DVTAwarenessMonth, reminding us to stay vigilant against deep vein thrombosis, a precursor to pulmonary embolism. Spread awareness, save lives. #DVT #PreventPE James Horowitz Brandon Hooks, D.O., FCCP F Mae West, MD MS

March marks #DVTAwarenessMonth, reminding us to stay vigilant against deep vein thrombosis, a precursor to pulmonary embolism. Spread awareness, save lives. #DVT #PreventPE

<a href="/jameshorowitzmd/">James Horowitz</a>
<a href="/DrHooksDO/">Brandon Hooks, D.O., FCCP</a>
<a href="/FMaeWestMD/">F Mae West, MD MS</a>
Benzidia Ilham (@benzidiai) 's Twitter Profile Photo

🚨 New study alert published in JACC Journals CI ! 🚨 Can superficial upper extremity venous access replace femoral access in ultrasound-assisted thrombolysis (USAT) for #PE ? ✅ 94% success ✅ Fewer complications 🔗 Read more: authors.elsevier.com/a/1kizs_i2X-PE… 🙏Andrew Hirsch et al.

Marc Carrier (@marccarrier1) 's Twitter Profile Photo

Prof. Mahé Isabelle presents API-CAT at #ACC2025, published in NEJM Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer. nejm.org/doi/full/10.10…

Prof. <a href="/isabellemahe1/">Mahé Isabelle</a> presents API-CAT at #ACC2025, published in <a href="/NEJM/">NEJM</a> Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer.
nejm.org/doi/full/10.10…